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Abstract
A reproducible method to inhibit allergic immune responses is accomplished with hi-dose Ag sensitization, via
intraperitoneal (IP) injection. However, the role of CD4+ CD25+ FoxP3+ T regulatory cells (Treg) in this process is
unknown, as is whether such modulation extends to ocular allergy. We therefore determined herein whether hi-dose
sensitization modulates ocular allergy, and whether CD4+ CD25+ FoxP3+ Treg are involved. C57BL/6 mice were IP
sensitized via low-dose (100 µg) versus hi-dose (1000 µg) ovalbumin (OVA), in aluminum hydroxide (1 mg) and
pertussis-toxin (300 ng). Other mice received anti-CD25 Ab (PC61) to ablate Treg during sensitization. In another
experiment, Treg from hi-dose sensitized mice were adoptively transferred into low-dose sensitized mice. Once daily
OVA challenges were administered. Clinical signs, IgE, T cell cytokines, and eosinophils were assessed. Data
revealed that hi-dose, but not low-dose, sensitization led to allergy modulation, indicated by decreased clinical signs,
serum IgE levels, Th2 recall responses, and eosinophil recruitment. T cells from hi-dose sensitized mice showed a
robust increase in TGF-b production, and Treg from these mice were able to efficiently suppress effector T cell
proliferation in vitro. In addition, in vivo Treg ablation in hi-dose sensitized mice revoked allergy modulation. Lastly,
Treg from hi-dose sensitized mice were able to adoptively transfer allergy modulation to their low-dose sensitized
counterparts. Collectively, these findings indicate that modulation to hi-dose sensitization, which is extended to ocular
allergy, occurs in a Treg-dependent manner. In addition, our data suggest that hi-dose sensitization may henceforth
facilitate the further examination of CD4+ CD25+ FoxP3+ Treg in allergic disease.
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Introduction
The biology of regulatory T cells (Treg) continues to be an
active area in allergy research and a focus to help further
understand potential contribution(s) to normal allergy
resistance and therapy. These naturally occurring immuno-
modulatory lymphocytes are of tremendous interest to the field
because of their crucial role in the maintenance of normal
immune homeostasis. Evidence for Treg in staving off
autoimmune diseases is widely appreciated, and likewise there
is literature supporting their role in modulation of T helper 2
(Th2) responses that mediate allergy [1]. Two main populations
of Treg which have received considerable attention, include (a.
CD4+ CD25+ FoxP3+ Treg; and (b. CD4+ IL-10 secreting Treg
(i.e. Tr1) [1,2].
Despite significant advances in this area, key aspects, such
as in FoxP3+ Treg function in allergy, remain incompletely
understood. For example, on the one hand, FoxP3+ Treg do
not appear to be involved in allergy regulation that occurs in
healthy individuals. Evidence for this was shown by Meiler et
al, as protection to hi-dose bee venom exposure in beekeepers
was mediated instead by Tr1 [3]. On the other hand, disruption
of FoxP3+ Treg is known to lead to dysregulation of allergic
immune responses, as evidenced to Foxp3 mutations in scurfy
mice and in humans (i.e. immune dysfunction,
polyendocrinopathy, enteropathy, X-linked syndrome) [4,5].
Thus, future work, which includes further development of
incisive animal models, continues to be a crucial component to
delineate such disparate Treg mechanisms, such as in allergy
modulation versus susceptibility.
HI-dose intraperitoneal sensitization in mice is a highly
reproducible model to induce an impairment of allergic Th2
responses [6-12], and thereby is of particular utility toward
elucidation of natural mechanisms that modulate allergy.
Evidence has led to the hypothesis that such an altered
response is merely a secondary effect of priming a Th1
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dominant response—which in turn suppresses other Th
subsets such as Th2 [6-8]. However, there are a number of
studies that have challenged this dogma with the observation
that an increased Th1 response was not observed in response
to hi-dose intraperitoneal sensitization [9-12]. Furthermore, it is
now widely appreciated that allergic immune responses are
contributed to by other Th subsets such as Th1 and Th17
[13-17]. Collectively, these reports point to the notion that a
Th1 dominant suppression cannot fully explain the allergy
modulation that arises from hi-dose intraperitoneal
sensitization.
Data from the current study show that Treg are central to
modulating ocular allergy in hi-dose intraperitoneal
sensitization. This is supported by our findings that Treg
ablation revokes allergy modulation afforded by hi-dose
intraperitoneal sensitization, and we also show that Treg from
hi-dose sensitized mice adoptively transfers this modulatory
effect. Thus, we conclude that Treg mediated tolerance is
responsible for the modulation of allergy responses arising
from hi-dose intraperitoneal sensitization. Collectively, our
findings reveal an important mechanism by which hi-dose
intraperitoneal sensitization modulates Th2 in allergy, and thus
support the use of hi-dose intraperitoneal sensitization as a
model for future studies of CD4+ CD25+ FoxP3+ Treg biology
and tolerance mechanisms relevant in allergy.
Materials and Methods
Animals and anesthesia
Eight to 10 week-old male C57BL/6 mice were purchased
from Charles River Laboratories (MA). Mice were kept in a
specific pathogen-free environment at the animal facility of
Schepens Eye Research Institute. The Institutional Animal
Care and Use Committee at Schepens Eye Research Institute
approved the experimental protocol, and all animals were
managed according to the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research. Anesthesia was
used for all surgical procedures with intraperitoneal
administered ketamine/xylazine suspensions (120 and 20
mg/kg, respectively). Euthanasia was performed in accordance
with American Veterinary Medical Association Guidelines for
Euthanasia of Animals. This was accomplished via carbon
dioxide asphyxiation with a precharged chamber, followed by a
secondary measure to ensure non-recovery accomplished by
bilateral thoracotomy.
Sensitization and ocular surface challenge to induce
ocular allergy
This model has been previously described [17]. Briefly,
C57BL/6 mice were sensitized via intraperitoneal injection once
with low-dose (100µg) or hi-dose (1000 µg) ovalbumin (OVA,
Sigma Aldrich). Injection included 1 mg aluminum hydroxide
(Sigma Aldrich), and 300 ng of pertussis toxin (Sigma Aldrich)
diluted in 100 µl PBS. Mice were rested for 2 wks and then
challenged by instillation of OVA eye drops (250 µg/5 µl) once
daily for at least 12 d.
Clinical scoring
This procedure has been previously described [17]. Briefly,
clinical evaluation of ocular allergy was performed in a masked
fashion for signs of immediate hypersensitivity responses 20
min after topical OVA challenge. Clinical evaluation was based
on four parameters, which included: lid swelling, tearing,
conjunctival chemosis, and conjunctival redness. The severity
of each parameter was graded from 0 (absent of signs) to 3+
(maximal) scale and the total score consisted of the sum of
these four parameters.
ELISA for sera OVA-specific IgE
Following topical challenge, blood was collected from
submandibular vein of mice and sera were isolated. Samples
were analyzed via ELISA for OVA-specific IgE according to the
manufacturer’s instructions (AbD Serotec, Raleigh, USA). In
some experiments, sera were analyzed via ELISA for total IgE
and performed according to manufacturer’s instructions
(Innovative Research Inc, Florida, USA).
Flow cytometric analysis of conjunctiva
This procedure has been described elsewhere [17]. Briefly,
mice were euthanized 20 min post challenge and surgically
procured ipsilateral conjunctivae (i.e. superior and inferior
bulbar, fornix, and palpebral regions) were collected. Tissues
were digested with 2 mg/ml collagenase type IV and 0.05
mg/ml DNase I (Roche, Basel, Switzerland) for 2 to 3 h at
37°C, as previously described. Suspension were run a through
a 70-µm cell strainer and then washed thoroughly. Cells were
resuspended in 0.5% BSA buffer, and followed by anti-FcR
(CD16/CD32) blockade as per manufacturer’s instructions (BD
Pharmingen). Cells were subsequently stained as per
manufacturer’s instructions with APC Cy7-conjugated anti-
CD45 Ab (clone 30-F11, Biolegend), and PE-conjugated
Siglec-F (clone F50-2440, BD Biosciences). Aliquots were
made for staining with appropriate isotype controls. All samples
were analyzed using a BD LSR II flow cytometer (BD
Biosciences).
Preparation of bone marrow-derived dendritic cells
(BMDC)
This procedure has been previously described [17]. Briefly,
femurs and tibia were removed from naïve C57BL/6 mice.
Bones were flushed by using a syringe filled with RPMI 1640 to
release bone marrow (BM) cells. Cells were washed thoroughly
and plated (2x105/ml) in RPMI1640 medium supplemented
with10% FBS, 1% penicillin/streptomycin, and 20ng/ml mouse
GM-CSF (Biolegend). Media was changed on day 4 and
loosely adherent cells were collected on day 7.
In vitro recall stimulation
This procedure is previously described [17]. Briefly,
ipsilateral LN (cervical and submandibular) were collected
following topical challenge. T cells were enriched for via MACS
sorting using anti-CD90.2 Ab according to manufacturer’s
instructions (Miltenyi Biotec). Enriched T cells were
enumerated via trypan blue exclusion assay, and plated in
Treg Modulation in Hi-Dose Allergen Sensitization
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round-bottom 96-well plate at a concentration of 1.25x106/ml.
OVA-pulsed immature BMDCs prepared as described above
were plated with T cells at a concentration 0.625x106/ml. In
some cultures, LN cells were left unfractionated and
subsequently stimulated with 1 mg/ml OVA (without addition of
BMDC). All cultures were plated in triplicate wells for up to 24
hr.
ELISA measurement of T cell cytokines
Cells were plated as indicated above. Following 24 hr OVA
stimulation, cultures were restimulated with PMA/ionomycin
(Sigma Aldrich) for up to 6 hours. Harvested supernatant was
measured via ELISA for IFN-g, IL-4, IL-5, IL-13, IL-10, and
TGF-b cytokines, as per manufacturer’s instructions (Ready-
set-go ELISA kit, eBioscience, San Diego, USA).
Intracellular flow cytometry for analyses of T cells in
vitro
Cells were plated as indicated above. Following 24 hr OVA
stimulation, cultures were restimulated with PMA/ionomycin
(Sigma Aldrich) and GolgiStop (BD Biosciences) for up to 6
hours. Cells were collected and stained with PerCP/Cy5.5
conjugated anti-CD4 antibody (cell surface) and stained
intracellularly with FITC conjugated anti-IFN-γ, PE/Cy7
conjugated anti-IL-4, PE conjugated anti-IL-5, and APC
conjugated with IL-13 antibodies (Biolegend, CA, USA) and
were analyzed with a flow cytometer, as described above.
Flow cytometric analyses of Treg
Following topical challenge, ipsilateral LN (cervical and
submandibular) were collected and pooled from freshly
euthanized mice. Cells were washed and stained for FITC-
conjugated anti-CD4, PE-conjugated anti-CD25, or PE/Cy5
conjugated anti-FoxP3 antibodies (eBioscience). Isotype
control was stained with appropriate-matched antibodies
(eBioscience). For nuclear staining of FoxP3, a cell fixation/
permeabilization kit (eBioscience) was used as per
manufacturer’s instruction.
Treg suppression assay
This procedure was modified from Chauhan et al [18].
Effector T cells (CD4+ CD25-) were MACS sorted from spleens
of low-dose (100 µg) OVA sensitized mice. Treg (CD4+
CD25+) were MACS sorted from LN of low- vs. hi-dose
sensitized mice post challenge. Treg from immunologically
naïve mice were also collected. Sorting was accomplished
using the Regulatory T Cell Isolation Kit (Miltenyi Biotec)
according to manufacturer’s specification. Co-cultures were
established with effector T cells (1 x 106), Treg (5 x 104), OVA
pulsed BMDC (1 x 105) in RPMI media including 10% FBS and
OVA (1mg/ml) for 3 days in 96-wells. Effector T cell
proliferation was evaluated with BrdU incorporation assay
according to manufacturer’s instructions (Millipore, MA, USA).
Percent Treg suppression = [(proliferation of effector T cells
cultured without Treg) – (proliferation of effector T cells cultured
with Treg)/ (proliferation of effector T cells cultured without
Treg)] x 100.
Adoptive transfer of Treg
This procedure was modified from Chauhan et al [18].
Sorting was accomplished using the Regulatory T Cell Isolation
Kit (Miltenyi Biotec) according to manufacturer’s specification.
Treg were MACS sorted from LN of low- vs. hi-dose sensitized
mice post challenge. Adoptive transfer of 5 x 105 Treg was
performed via intravenous tail vein injection of recipient mice.
Recipient mice were sensitized with low-dose intraperitoneal
OVA (100 µg) 2 wk prior to adoptive transfer.
In vivo Treg depletion
CD4+ CD25+ T cells were depleted in vivo via intraperitoneal
administration of 1.0 mg of anti-CD25 mAb (PC61; BioXcell,
NH, USA) or isotype control Ab (rat anti-mouse IgG1 antibody)
2 d prior to, on the day of, and 7 d after hi-dose OVA
sensitization. Depletion of CD4+ CD25+ cells was confirmed in
spleen and LNs by flow cytometry.
Statistical analyses
Graphical data presented throughout are expressed as the
mean ± standard error of the mean (SEM). A p< 0.05 was
considered statistically significant. Statistical difference was
analyzed with the Kruskal-Wallis test, ANOVA or two-tailed
student t-test as indicated. Prism software (version 5.0;
GraphPad) was used. Normality was tested by Kolmogorov-
Smirnov test (Z = 1.166; Asymp. Sig 2-tailed = 0.132).
Results
Hi-dose allergen sensitization leads to suppression of
allergic immune responses in the mouse model of
ocular allergy
We first determined whether hi-dose allergen sensitization
leads to suppression of allergic immune responses that cause
ocular allergy. To test this, we relied on our model previously
reported demonstrating robust ocular allergy responses to
topical challenges of OVA eye drops in mice that had received
intraperitoneal sensitization with low-dose OVA (100 µg OVA)
[17]. In the current study, we increased this dose 10-fold, to
1000 µg of OVA, to generate the hi-dose allergen sensitization
regimen. Two weeks following hi-dose versus low-dose
sensitization, mice were challenged topically with OVA eye
drops once daily for more than 18 d (Figure 1). To assess the
effect of dose level on ocular allergy clinical signs, mice were
scored in a masked fashion for clinical signs (i.e., conjunctival
chemosis, hyperemia, lid edema, and tearing/discharge) 20
min post challenge [17]. Non-sensitized mice were also
challenged as a negative control.
Results from this experiment demonstrated a statistically
significant (p<0.05) increase for low sensitization over no
sensitization controls on Challenge Days 4, 8, 12, 14, 16, and
18 (Figure 1). This trend was maintained until termination of
experiment on day 28 (data not shown). Clinical responses in
low-dose sensitization were also statistically greater than those
of hi-dose sensitization on Challenge days 8, 12, 14, 16, and
18 (Figure 1). This trend was also maintained though
termination on day 28 (data not shown). Taken together these
Treg Modulation in Hi-Dose Allergen Sensitization
PLOS ONE | www.plosone.org 3 September 2013 | Volume 8 | Issue 9 | e75769
results indicate that hi-dose OVA sensitization leads to
impaired clinical signs as compared to low-dose OVA
sensitized mice, relative to levels seen with challenging non-
sensitized mice.
We next determined the effect of hi-dose allergen
sensitization on allergic immune responses in the ocular allergy
model. Thus, hi- versus low-dose sensitized mice were
challenged topically and euthanized for collection of
conjunctivae, sera, and LN. Conjunctivae were harvested to
enumerate eosinophils (CD45+ Siglec-F+) [19] via flow
cytometry. Sera were collected to evaluate OVA specific IgE
levels via ELISA. Draining LN were collected so that T cells
could be stimulated with OVA in vitro for supernatant
quantitation of IL-4, IL-5, and IL-13 via ELISA.
For conjunctiva, we observed an approximate 20-fold
decrease in the frequency of eosinophils, from 23.7% in low-
dose sensitized mice to 1.26% in hi-dose allergen sensitization
(Figure 2 a). Data from repeated experiments are shown in
Figure S1 (a). Similarly for the sera, we found a statistically
significant reduction in OVA specific IgE in hi-dose allergen
sensitized mice, as compared to low-dose sensitization (Figure
2 b). In addition, T cells from hi-dose sensitized mice displayed
reduced IL-4 and IL-13 levels in vitro to OVA stimulation
(Figure 2 c). Taken together, these data indicate that hi-dose
allergen sensitization leads to a suppression of allergic
immunity and clinical responses in ocular allergy.
Figure 1.  Hi-dose intraperitoneal sensitization suppresses
clinical signs of ocular allergy.  Mice were intraperitonealy
sensitized with OVA/Alum with either hi-dose OVA (1000 µg) or
low-dose OVA (100 µg), or left naïve as a control. All mice
were rested for 2 weeks and then OVA challenged (including
the control) with instillation of OVA eye drops once/d (i.e.
Challenge Days) for 18 d. Mice were scored, in a masked
fashion, 20 min post challenge for clinical signs (i.e.,
conjunctival chemosis, hyperemia, lid edema, and tearing/
discharge). Data are presented as mean and SEM. Graph
shows the results from one experiment (n=4/group), and is
representative of 3 independent experiments. Statistical
significance was computed via student’s t-test for low-dose
sensitization versus no sensitization (+ p<0.05), or hi-dose
sensitization (*p<0.05).
doi: 10.1371/journal.pone.0075769.g001
Hi-dose allergen sensitization is associated with
increased Treg activity
Having identified that hi-dose allergen sensitization leads to
allergy modulation in ocular allergy, we next set out to begin
determining by which mechanism(s) this may occur. Particular
cytokine milieus to explain such suppression in ocular allergy
can include an IFN-g mediated (i.e., via Th1 polarization), IL-10
mediated (i.e. via Tr1 cells), and/or a TGF-b mediated (i.e., via
CD4+ CD25+ FoxP3+ Treg) processes. To examine this, hi-
versus low-dose sensitized mice were challenged and LN T
cells were stimulated in vitro with OVA for quantitation of
culture supernatant IFN-g, IL-10, and TGF-b levels via ELISA.
Figure 2.  Allergic immune responses are suppressed in
response to hi-dose intraperitoneal sensitization.  (A) Hi-
dose intraperitoneal sensitization leads to impaired eosinophil
infiltration. Excised conjunctivae of topically challenged eyes
were pooled (n=4 mice/group) and prepared into single-cell
suspensions for flow cytometric analysis for CD45 and Siglec-F
[19]. (B) Hi-dose intraperitoneal sensitization confers impaired
OVA specific IgE levels. Sera were collected from topically
challenged mice and pooled (n=4 mice/group) to assess OVA
specific IgE via ELISA. Data are presented as the mean and
SEM (*p<0.05). (C) Hi-dose intraperitoneal sensitization
suppresses Th2 immune responses. Purified T cells pooled
(n=4 mice/group) were stimulated in triplicate wells for 24 h
with OVA-pulsed BMDC and then PMA/ionomycin for up to 6
hr. Indicated cytokines in culture supernatants were quantitated
by ELISA. Data are presented as the mean and SEM
(*p<0.05). (A, B, C) Data presented are from one experiment,
which are representative of at least 2 two independent
experiments.
doi: 10.1371/journal.pone.0075769.g002
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In doing so, we observed that IFN-g levels were significantly
decreased in T cells from hi-dose allergen sensitization relative
to those from low-dose sensitization (Figure 3 a). In contrast,
we also observed that IL-10 levels were increased in T cells
from hi- versus low-dose sensitization (Figure 3 a). Strikingly,
however, we found an approximate 5-fold increase in TGF-b
levels in T cells from hi-dose sensitization relative to low dose
sensitization (Figure 3 a). These data suggested a possible
role for CD4+ CD25+ FoxP3+ Treg in hi-dose allergen induced
suppression of ocular allergy.
Treg frequencies and function were next assessed to
examine whether these cells are associated functionally with
the allergy modulation in ocular allergy that occurs to hi-dose
allergen sensitization. To accomplish this, LN from challenged
mice sensitized with low- vs. hi-dose allergen were evaluated
via flow cytometry to enumerate Treg frequencies. In doing so,
we observed increased frequencies of CD4+ CD25+ FoxP3+
Treg in hi-dose allergen sensitized mice (23%), as compared to
low-dose allergen sensitized mice (16%) (Figure 3 b).
In addition, we determined the effect of hi-dose sensitization
on Treg suppressor function, i.e. ability to suppress T cell
proliferation [18]. This was accomplished by stimulating
proliferation in vitro with OVA-pulsed BMDC of sorted effector T
cells (CD4+ CD25-) originating from sensitized mice, and
adding sorted Treg (CD4+ CD25+) from hi- versus low-dose
sensitized. Treg from naïve mice were also compared as a
baseline. Suppression of T cell proliferation by Treg was
quantitated by BrdU incorporation assay relative to T cell
proliferation in the absence of Treg [18]. Results demonstrated
that %Treg suppression from hi-dose sensitized mice was
significantly higher than those from naïve mice (Figure 3 c);
thus, indicating increased Treg suppressor function from hi-
dose sensitized mice. In contrast, %Treg suppression from low-
dose allergen sensitized mice was not significantly higher than
that of Treg from naïve mice (Figure 3 c). Taken together,
these data indicate elevated Treg activity (i.e. increased
frequencies in the LN and increased suppressor function in
vitro) is associated with allergy modulation in ocular allergy that
occurs to hi-dose allergen sensitization.
Ablation of Treg during hi-dose sensitization revokes
allergy modulation in the ocular allergy model
Augmented Treg activity evidenced in association with
allergy modulation in ocular allergy that occurs to hi-dose
suggested an important role for Treg in this process. To further
evaluate this, we determined the effect of Treg ablation during
hi-dose allergen sensitization on allergic immune responses
and ocular allergy. Treg were ablated by in vivo administration
of anti-CD25 Ab blockade (PC61) [20,21] (versus isotype
control) in hi-dose sensitization, and we confirmed their
resultant absence via flow cytometry of CD4+ CD25+ FoxP3+
(data not shown). Low-dose allergen sensitized mice that did
not receive Ab were also included as a control. All mice were
challenged once daily and clinically scored in a masked fashion
at 20 min post challenge (Figure 4 a). Interestingly, we
observed that the suppression of ocular allergy clinical signs
afforded by hi-dose allergen sensitization was lost as a result of
Treg ablation, as clinical scores were identical to those seen in
low-dose sensitized mice (Figure 4 b). This was in contrast to
hi-dose sensitized mice treated with isotype control Ab, which
maintained their modulation as exhibited by significantly lower
clinical signs relative to those seen in low-dose sensitized mice
(Figure 4 b).
For eosinophil infiltration, we observed a 3.5% population of
eosinophils in hi-dose sensitized mice administered with
Figure 3.  Allergy modulation in hi-dose intraperitoneal
sensitization is associated with augmented Treg
activity.  (A) Increased TGF-b expression by T cells in
response to hi-dose intraperitoneal sensitization. Purified T
cells pooled (n=4 mice/group) were stimulated in triplicate wells
for 24 h to OVA-pulsed BMDC and then restimulated with PMA/
ionomycin for up to 6 hr. Indicated cytokines in culture
supernatants were quantitated by ELISA. Data are presented
as the mean and SEM (*p<0.05) (B) Hi-dose intraperitoneal
sensitization is associated with increased frequencies of Treg
(CD4+ CD25+ FoxP3+). Pooled draining LNs (n=4 mice/group)
were analyzed via flow cytometry. (C) Treg in hi-dose
intraperitoneal sensitization confers increased suppression of
effector T cell proliferation in vitro. Sorted effector T cells
(CD4+ CD25-) from sensitized mice were stimulated in vitro
with OVA-pulsed BMDCs. Sorted Treg (CD4+ CD25+) pooled
(n=4 mice/group) were added to cultures. Suppression of T cell
proliferation by Treg was quantitated by BrdU incorporation
assay relative to T cell proliferation in the absence of Treg.
Data are presented as the mean and SEM (*p<0.05). (A, B, C)
Data presented are from one experiment, which are
representative of at least 2 two independent experiments.
doi: 10.1371/journal.pone.0075769.g003
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Figure 4.  Treg ablation during hi-dose sensitization leads
to loss of allergy modulation.  (A, B) Treg were ablated via
anti-CD25 Ab (PC61) administration or isotype Ab in hi-dose
intraperitoneal sensitized mice and compared to mice that
received low-dose intraperitoneal sensitization (n=4mice /
group). All mice were challenged once/d and scored for clinical
signs in a masked fashion approximately 20 min post
challenge. Data are presented as mean and SEM. Statistical
significance was computed via student’s t-test for hi-dose
sensitized mice treated with isotype vs. anti-CD25 Ab
(*p<0.05). (C) Suppression of eosinophil infiltration is lost when
Treg are ablated during hi-dose intraperitoneal sensitization.
Each plot is derived from pooled conjunctivae of an n=4 per
group. Data presented is from one experiment, which is
representative of two independent experiments. (D)
Suppression of T cell responses is lost when Treg are ablated
during hi-dose intraperitoneal sensitization. LN cells pooled
(n=4 mice/group) were restimulated in vitro with OVA for 24 h
and then PMA/ionomycin/brefeldin A for up to 6 hours. Flow
cytometry was used to quantify frequencies of CD4+ IFN-g+,
CD4+ IL-5+, CD4+ IL-4+, and CD4+ IL-5+ T cells. Plots show
the results from one experiment (n=4/group), and are
representative of 2 independent experiments.
doi: 10.1371/journal.pone.0075769.g004
isotype Ab (Figure 4 c); whereas eosinophils increased to
13.1% in hi-dose sensitized mice treated with anti-CD25 Ab
(Figure 4 c). The latter was similar to levels seen in low-dose
sensitized mice (9.7%) (Figure 4 c). Data from repeated
experiments are shown in Figure S1 (b). Likewise, T cell
cytokines to in vitro recall, and conjunctival eosinophil
infiltration were examined. We found that hi-dose sensitized
mice treated with anti-CD25 Ab showed cytokine levels (i.e.,
IL-4, 5, 13, and IFN-g) similar to those seen to low dose
allergen sensitization (Figure 4 d); whereas hi-dose sensitized
mice treated with the isotype control Ab showed suppressed
cytokine levels (Figure 4 d). T cell data are summarized in
graph form in Figure S1 (c).
Treg from hi-dose allergen sensitized mice adoptively
transfers allergy modulation to low-dose allergen
sensitized mice
Having demonstrated evidence for a Treg requirement in
ocular allergy modulation arising from hi-dose allergen
sensitization, we next set out to determine whether Treg from
hi-dose sensitized mice can adoptively transfer suppression to
low-dose allergen sensitized mice. To accomplish this, low-
dose allergen sensitized mice were adoptively transferred with
Treg from hi-dose sensitized mice versus Treg from low-dose
sensitized mice (Figure 5 a). Low-dose sensitized mice not
adoptively transferred were also included as a control (Figure 5
a). All mice were challenged topically once daily and scored
clinically in a masked fashion 20 min post challenge. In
addition, mice were euthanized and conjunctivae collected for
flow cytometric analysis to enumerate eosinophil infiltration.
Results from this experiment revealed that adoptive transfer of
hi-dose Treg caused a significant suppression of clinical signs
relative to low-dose sensitized mice that were not adoptively
transferred (Figure 5 b). This is in contrast to adoptive transfer
of Treg from low-dose sensitized mice, which resulted in only a
modest to marginal suppression of clinical signs (Figure 5 b).
Data from flow cytometry analysis of conjunctiva showed that
adoptive transfer of Treg from hi-dose sensitized mice led to
impairment in eosinophil infiltration (14.4%) as compared to
mice that received Treg from low-dose sensitized mice (29.0%)
(Figure 5 c). Taken together, these data therefore indicate that
Treg from hi-dose allergen sensitized mice adoptively transfers
hi-dose allergen induced modulation to low-dose allergen
sensitized mice.
Discussion
Modulation of Th2 in allergy to hi-dose intraperitoneal
sensitization has been previously appreciated, albeit shown
here for the first time to also be relevant in the murine ocular
allergy model. However, until now, a role for CD4+ CD25+
FoxP3+ Treg has not been shown. Allergy modulation to hi-
dose intraperitoneal sensitization was previously hypothesized
to occur as a mere secondary effect of priming a Th1-dominant
response—which can in turn suppress other Th subsets such
as Th2 [6-8]. However, Th1 polarization cannot fully explain
this effect. Indeed, other T helper lymphocyte subsets, i.e. Th1
and Th17, are widely appreciated to also play an important role
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in allergy immunopathogenesis [13-16]—although the role of
Th17/IL-17, if any, in ocular allergy remains unclear [23].
Furthermore, we present strong evidence that indicate a central
role for Treg (CD4+ CD25+ FoxP3+) in mediating allergy
modulation in ocular allergy to hi-dose intraperitoneal
sensitization. Evidence to support this includes our finding that
Treg ablation revokes hi-dose sensitization induced modulation
in ocular allergy, and we also show that Treg from hi-dose
sensitized mice adoptively transfers this modulatory effect.
Thus, given the central role of Treg that was revealed in this
study, we have concluded that allergy modulation in ocular
allergy arising from hi-dose intraperitoneal sensitization is
principally a Treg mediated tolerance.
Figure 5.  Treg from hi-dose sensitized mice adoptively
transfers allergy modulation to low-dose sensitized
mice.  (A, B) Low-dose intraperitoneal sensitized mice were
adoptively transferred with Treg (5 x 105) from hi-dose versus
low-dose intraperitoneal sensitized mice. Low-dose
intraperitoneal sensitized mice without adoptive transfer were
included as a control. All mice were challenged once/d and
scored for clinical signs in a masked fashion approximately 20
min post challenge. Graph shows the results from one
experiment (n=4/group), and is representative of 2 independent
experiments. Statistical significance was computed via
student’s t-test for low-dose sensitized mice transferred with lo-
dose vs. hi-dose Treg (*p<0.05). (C) Adoptive transfer of Treg
from hi-dose intraperitoneal sensitized mice conferred
suppression of eosinophil infiltration. Each plot is derived from
pooled conjunctivae of an n=4 per group. Data presented is
from one experiment, which is representative of two
independent experiments.
doi: 10.1371/journal.pone.0075769.g005
The first clue that implicated this was our initial findings
demonstrating that hi-dose intraperitoneal sensitization leads to
impaired ocular allergy clinical signs. This was associated with
decreased eosinophil recruitment, decreased Th2 cytokines to
recall in vitro stimulation, and reduction in sera IgE levels.
Consistent with our findings, Aguilar-Pimentel et al and others
have shown that hi-dose intraperitoneal sensitization leads to
modulation of Th2 in the allergic asthma model [12]. Data
herein suggest that this effect in our model was not associated
with a dominant Th1 response, as hi-dose sensitization was
found here to have suppressed IFN-g levels indicated by recall
stimulation of LN T cells in vitro. This is in line with work by
Sakai et al (as well as by Morakata et al) in the allergic asthma
model, who reported suppressed IFN-g levels to in vitro recall
stimulation of splenocytes from hi-dose (1000 µg OVA) allergen
sensitized mice [10,11]. It is noteworthy, however, that both
Sakai and Morakata et al found that IFN-g levels were not
suppressed in lung homogenate or bronchial lavage of hi-dose
sensitized mice [10,11]. While the reasons for this are not
clear, the current study has revealed multiple lines of evidence
indicative of a central Treg role being principally responsible for
allergy modulation in hi-dose intraperitoneal sensitization.
Initial direct evidence to suggest a central role for CD4+
CD25+ FoxP3+ Treg in this modulatory response was our
identification of very high expression levels of TGF-b by T cells
to recall allergen stimulation in vitro. We observed a near 5-fold
increase in TGF-b levels in T cells from hi-dose as compared to
low-dose sensitized mice, whereas the increase in IL-10 levels
was less than 0.25-fold.
Furthermore, we also observed increased CD4+ CD25+
FoxP3+ Treg frequencies in the LN, which suggests expansion
of inducible Treg corresponding with previous reports [24,25].
Interestingly, our findings point to the possibility that the
increased Treg frequencies may not be solely responsible for
modulation, as increased suppressor function of Treg from hi-
dose sensitized mice was also observed here. Thus, hi-dose
allergen sensitization augments Treg activity via increased
suppressor function and expansion of Treg. This is somewhat
different to CD4+ CD25+ FoxP3+ Treg that mediate Th1
modulation in promotion of corneal transplant survival, which is
associated with increased suppressor function, but not
increased Treg frequencies [18].
Data from our Treg ablation studies further supported the
conclusion that Treg play a central role in allergy modulation
arising from hi-dose intraperitoneal sensitization. Treg ablation
was performed via administration of anti-CD25 Ab (PC61)
blockade [20-22] 2 d prior to, on the day of, and 7 d post
administration of hi-dose allergen immunization—a regimen
which we confirmed to systemically ablate Treg (data not
shown). Results of this experiment showed that allergy
modulation was lost when Treg were ablated during hi-dose
allergen sensitization. Increased clinical scores, eosinophil
recruitment, and IL-4, -5, -13 and IFN-g cytokine levels to recall
stimulation, indicated this. Our findings are in line with
Boudousquié et al, demonstrating anti-CD25 Ab ablation of
Treg impairs modulation arising from intranasal allergen
treatment in the allergic asthma model [24]. Relatedly, Leech et
al reported that Treg ablation using anti-CD25 Ab blockade in
Treg Modulation in Hi-Dose Allergen Sensitization
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intraperitoneal sensitized mice led to impaired allergic asthma
resolution [26].
Perhaps the strongest line of evidence in the current study to
implicate a central Treg role in allergy modulation in ocular
allergy arising from hi-dose intraperitoneal sensitization is the
adoptive transfer experiments performed. Indeed, numerous
converging reports have already demonstrated protection from
allergic immune responses via adoptive transfer of Treg from
naïve mice [24-27]. Interestingly, we found that modulation of
Th2 responses in low-dose sensitized mice was adoptively
transferred with Treg harvested from hi-dose allergen
sensitized mice—but only marginally so to those from low-dose
sensitized mice. These data demonstrate that it is not simply
the action of Treg adoptive transfer in our model that mediates
fulminant modulation, but rather it is the Treg induced by hi-
dose intraperitoneal sensitization that mediates this effect.
Collectively, we show for the first time that Treg are central to
allergy modulation arising from hi-dose intraperitoneal
sensitization, and demonstrated this in the murine model of
ocular allergy [17,28,29]. We found that hi-dose allergen
sensitization leads to impairment of allergic immune responses
and ocular allergy clinical signs. Treg ablation revokes hi dose
sensitization-induced modulation, and Treg from hi-dose
sensitized mice effectively transfers this modulatory effect to
low-dose sensitized mice. Thus, we conclude that allergy
modulation arising from hi-dose intraperitoneal sensitization is
principally a Treg-mediated tolerance. Thus, our findings
elucidate the mechanism by which hi-dose intraperitoneal
sensitization leads to allergy modulation. Furthermore, these
results promote the future use of hi-dose intraperitoneal
sensitization to further elucidate the role of tolerance and Treg
in allergy modulation.
Supporting Information
Figure S1.  (A) Experimental repeats from data depicted in
Figure 2a. Eosinophil quantitation by flow cytometry analysis of
CD45+ Siglec F+ cells from conjunctivae of the indicated
groups. (B) Experimental repeats from data depicted in Figure
4c. (C) Flow cytometry data of experimental repeats depicted
in Figure 4d. Y-axes are %cytokine+ (e.g. IFN-g) of CD4+ T
cells.
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